Peptron & Seers Rally Amid 'Third Oil Shock' Fears[K-Bio Pulse]

[Han Kwangbeom, Edaily Reporter] Pharma and Bio stocks generally decline due to rising costs, but Peptron and Seers Technology gain on global partnerships and tangible performance.

On March 9, 2026, the South Korean stock market faced a significant downturn as tensions in the Middle East escalated fueling fears of a potential "Third Oil Shock."

While the broader pharmaceutical and biotech sectors struggled under the weight of rising raw material (API) costs and logistical burdens Peptron and Seers Technology defied the market trend buoyed by their respective individual growth catalysts.

Peptron stock trend on Mar 9.(Image=MP Doctor)

Peptron Surges on News of Government-Eli Lilly Strategic Collaboration

According to MP DOCTOR (formerly Marketpoint), Peptron closed at 285,000 KRW, up 8.37% from the previous day marking one of the highest gains in the pharma bio sector. Market analysts attribute this rally to the Memorandum of Understanding (MOU) signed on Monday afternoon between South Korea’s Ministry of Health and Welfare (MOHW) and the global pharmaceutical giant Eli Lilly and Company.

The MOU aims to advance South Korea’s pharmaceutical industry and improve public health. Under the agreement Eli Lilly plans to invest a total of $500 million over the next five years to strengthen the domestic bio innovation ecosystem.

A key highlight of the partnership is the planned establishment of "Lilly Gateway Labs," a global biotech incubation platform, in South Korea. This initiative is expected to create a highly favorable research environment for domestic companies already collaborating with big pharma.

Peptron is currently conducting joint research with Eli Lilly to extend the dosing interval of peptide based drug candidates specifically for obesity treatments using its proprietary long-acting drug delivery platform, "SmartDepo."

The technology aims to improve the current weekly injection regimen to once a month or longer. If commercialized, this could significantly enhance competitiveness in the global obesity treatment market. The government Lilly MOU has bolstered market confidence in Peptron’s ongoing research sustaining its upward momentum for the third consecutive session.

Seers Technology stock trend on Mar 9.(Image=MP Doctor)

Seers Technology Proves Growth with ‘thynC’ Expansion and Innovative Tech

Seers Technology also maintained an upward trajectory, closing at 129,700 KRW, up 5.53%. The company, specializing in wearable AI diagnostic monitoring recently garnered significant investor attention by announcing that its inpatient monitoring platform "thynC" has been adopted by over 30 hospitals, securing approximately 3,000 additional beds in January alone.

The rise in Seers Technology's stock price reflects the expanding application of its technology in clinical settings. Following its first contract with one of Korea’s "Big 5" hospitals last year, the company has seen a surge in new orders and system expansions since early 2026.

This shift from ward level pilot programs to hospital-wide implementations is seen as a sign of matured operational stability in large-scale medical environments.

A defining feature of Seers Technology is its fixed wireless gateway based monitoring system. Unlike other mobile based systems thynC utilizes gateways permanently installed in hospital wards to collect patient data continuously.

This structural stability minimizes the risk of signal disconnection and integrates seamlessly with existing hospital infrastructure, lowering the barrier to adoption. Furthermore its direct compatibility with Electronic Medical Record (EMR) systems allows real-time data synchronization with medical staff workflows.

The business model of Seers Technology is also viewed favorably as it generates recurring revenue through sensor sales and AI analysis subscriptions that scale with the number of beds. With the Middle East crisis driving up operational costs for hospitals Seers' focus on improving efficiency and reducing labor burdens has reframed the company as a "cost-reduction solution."

The rallies of these two companies underscore a "selection and concentration" trend in the market. As global uncertainties mount investors are pivoting away from speculative stocks and toward companies with confirmed technological competitiveness and tangible business expansion.

"In an environment of heightened macro uncertainty, the market is responding more sensitively to concrete evidence like actual order data and global partnerships rather than vague expectations" an industry official noted. "Moving forward, the performance gap between companies is likely to widen based on their technological maturity and commercialization milestones."